ATHLETES worldwide have received clarity regarding the use of popular weight-loss medications as the World Anti-Doping Agency (WADA) released its updated prohibited list for 2027. In a move that maintains the status quo for the high-profile GLP-1 receptor agonist class—which includes the globally recognized Ozempic and Mounjaro—WADA has opted to keep these substances on its monitoring program rather than moving them to the prohibited list.
The decision, which comes into effect on January 1, 2027, will be binding for all signatories of the World Anti-Doping Code, including the National Anti-Doping Agency (NADA) in India. While the regulatory body has cleared the path for athletes to continue using these medications for legitimate medical purposes, the agency has stopped short of providing an unconditional green light, highlighting the potential for abuse and the need for rigorous medical oversight.
A Measured Approach to Weight-Loss Drugs
Ozempic and Mounjaro have surged in popularity in recent years, primarily as treatments for Type 2 diabetes and as potent tools for weight management. As the usage of these GLP-1 receptor agonists has permeated the broader population, the sporting world has scrutinized their potential impact on athletic performance and health.
Olivier Rabin, WADA’s Senior Director of Science and Medicine, explained that the agency’s Prohibited List Expert Advisory Group and the Executive Committee engaged in an exhaustive review of these substances. Despite the intense scrutiny, WADA concluded that current scientific evidence does not yet justify a full ban.
“The prohibited list expert advisory group and the ExCo considered the status of GLP-1 receptor agonists carefully,” Rabin stated. “At this stage, the existing evidence was insufficient to justify a prohibition.”
However, Rabin issued a sharp warning to the global athletic community. He emphasized that the absence of a ban does not equate to an endorsement of indiscriminate use. Athletes are cautioned against utilizing these drugs without strict professional medical supervision, as the substances exert significant physiological effects that could pose serious health risks to individuals, particularly those pushing their bodies to the physical limit in elite competitions. WADA has confirmed it will commission further, extensive research to monitor these effects and ensure that the integrity of clean sport remains protected.
The Criteria for Prohibition
The decision-making process behind the WADA prohibited list is anchored in a strict, three-pronged test. For any substance or method to be officially banned, it must meet at least two of the following three criteria: the potential to enhance performance, the potential to pose a health risk to the athlete, or a violation of the “spirit of sport.”
By keeping GLP-1 receptor agonists on the monitoring program rather than the prohibited list, WADA is signaling that these substances currently do not meet the threshold required for a ban. The monitoring program acts as an intelligence-gathering tool, allowing WADA to track patterns of use and analyze whether the drugs are being leveraged by athletes to gain an unfair advantage or if their prevalence in sport is expanding to a level that threatens the health of competitors.
Updates to Glucocorticoids and Cannabis
The 2027 update brings further clarifications to the regulations surrounding other commonly discussed substances. Among the notable changes is a move to explicitly permit the vaginal administration of glucocorticoids. Previously, the rules regarding the administration routes of these anti-inflammatory drugs were a source of confusion for many athletes and medical teams. While other routes of administration remain subject to specific restrictions, this adjustment streamlines the regulations for those requiring such treatment.
Furthermore, the agency has maintained its existing stance on cannabinoids. Cannabidiol (CBD) remains permitted for use, reflecting the ongoing global shift in how non-psychoactive cannabis components are viewed. However, the agency reminded athletes that the primary psychoactive compounds found in cannabis—including those in marijuana and hashish—along with stimulants like cocaine, remain strictly prohibited during in-competition periods.
What This Means for the Future of Sport
As the January 1, 2027 deadline approaches, athletes and their support staff are encouraged to consult their respective anti-doping organizations to ensure full compliance. The decision to keep GLP-1 receptor agonists off the prohibited list provides immediate relief for those currently utilizing these treatments for documented health conditions. However, the athletic community should be aware that the landscape of doping control is fluid.
WADA’s commitment to ongoing research suggests that the status of these medications will remain under a microscope. As the science surrounding metabolic drugs evolves, so too will the regulatory framework intended to ensure that sport remains a competition of natural talent, training, and dedication. For now, the message from WADA is clear: while science catches up, caution and transparency remain the athlete’s best defense.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
